Preventing CO-197 Denials on Biologics & Phototherapy

Receiving a Claim Adjustment Reason Code (CARC) CO-197 indicates that a service was denied because the required pre-certification, authorization, or prior notification was absent, late, or mismatched. In dermatology, this denial hits two treatment categories hardest: high-cost biologic or systemic therapies and recurring phototherapy series. Because these modalities represent significant drug costs or multi-visit utilization schedules, resolving a CO-197 after administration is complex, resource-heavy, and often results in unrecoverable write-offs.

The Operational Breakdown Behind CO-197 in Dermatology

CO-197 denials rarely occur because the clinical team forgot that a drug or series required approval. Instead, they stem from administrative mismatches between what the payer approved and what was billed on the CMS-1500 or 837P electronic transaction.

For dermatology practices, the breakdown typically traces to specific workflow gaps:

• Payer Benefit Routing Errors: Submitting a buy-and-bill J-code (such as infliximab, ustekinumab, or certolizumab) through the medical benefit when the payer mandates a specialty pharmacy white-bagging model under the pharmacy benefit (or vice versa).
• Missing or Truncated Authorization Numbers: Billing teams omitting the 11-digit or alpha-numeric prior authorization (PA) number in Box 23 of the CMS-1500 or Loop 2300 (REF*G1 segment) on electronic 837P files.
• Authorization Expiration Mid-Cycle: Treating chronic plaque psoriasis or atopic dermatitis patients whose authorizations expired at the 6- or 12-month mark without a re-authorization triggered 45 to 60 days in advance.
• Unit and Frequency Misalignments: Obtaining approval for a loading dose schedule but failing to secure separate authorization for maintenance dosing, or exceeding the maximum authorized visits for phototherapy (CPT 96900, 96910, 96912).
• Site of Service or NPI Mismatches: Securing a PA under the supervising physician's rendering NPI, but billing the claim under an advanced practice provider (PA-C or NP), or listing a different physical location than the one certified on the authorization letter.

Understanding the mechanics of resolving dermatology CO-197 denial codes requires auditing these structural touchpoints across the clinical and administrative revenue cycle.

Biologic Workflows: Securing In-Office and Specialty Rx Authorizations

Biologics require distinct workflows depending on whether the medication is administered in-office via buy-and-bill or self-administered by the patient via a specialty pharmacy.

Buy-and-Bill Biologics (Medical Benefit)

When the practice purchases, stores, and administers biologic infusions or injections:

• Verification of Specific HCPCS Codes: Obtain prior authorization specifically for the relevant HCPCS J-code or Q-code, along with its specific national drug code (NDC) and unit count. If an authorization specifies standard maintenance units, administering an initial double-dose loading volume will trigger a CO-197 on the excess units.
• Strict Schedule Tracking: Loading doses often require separate authorization spans from maintenance phases. The authorization management system must track not just start and end dates, but also allowed unit caps per date of service.
• Cross-Referencing Rendering Clinicians: Commercial payers and Medicaid managed care plans frequently link authorizations directly to the prescribing provider’s Individual NPI. If an injection visit is billed incident-to or under a covering physician, verify whether the payer allows cross-coverage under the original authorization number.

Specialty Pharmacy / White-Bagging (Pharmacy Benefit)

When a specialty pharmacy ships patient-specific medication to the clinic for in-office administration:

• Separate the Drug from the Administration: The specialty pharmacy secures the drug authorization through the pharmacy benefit manager (PBM). However, the practice must verify whether the payer also requires a separate medical prior authorization for the administration CPT code (such as CPT 96372 for therapeutic subcutaneous injection or CPT 96413 for chemotherapy/complex biologic administration).
• Proof of Delivery Verification: Never administer a specialty pharmacy drug until the clinic receives delivery confirmation matching the patient’s name, exact dosage, and lot number to prevent billing unlinked administration codes.

Phototherapy Workflows: Managing Unit Caps and Medical Necessity

Phototherapy (CPT 96900 for broad/narrowband UVB, CPT 96910 for PUVA, and CPT 96912 for systemic PUVA) presents high risk for CO-197 denials due to the frequency of visits. Many commercial payers and Medicare Advantage plans require prior authorization for phototherapy beyond an initial evaluation period.

To avoid automated claim rejections during a phototherapy course:

• Visit-Count Tracking Rules: Most phototherapy authorizations grant a specific number of treatments (for example, 30 sessions over a 12-week span). The practice management system must increment and count each billed encounter against this threshold. Staff must flag the chart when the patient reaches five visits remaining.
• PASI and BSA Documentation: Re-authorization for phototherapy requires documented clinical progress. Clinical staff must capture objective disease severity metrics—such as Body Surface Area (BSA) percentage, Physician Global Assessment (PGA), or Psoriasis Area and Severity Index (PASI)—in the clinical note every 30 days. Payers deny continuation requests lacking measurable improvement data.
• Handling Unused Authorizations: If a patient misses consecutive weeks of phototherapy due to illness or non-compliance, their authorization timeline may expire before they complete the approved number of sessions. Administrative staff must request a date-span extension before billing resumes.

Immediate Controls to Implement This Week

Dermatology practices can implement several practical controls immediately to stop the flow of CO-197 denials:

• Mandate Clearinghouse Scrubbing Rules: Configure electronic claim scrubber rules to halt any claim containing CPT codes 96900, 96910, 96912, or dermatology-specific J-codes if Box 23 (prior authorization field) is blank.
• Establish a 45-Day Biologic Recertification Queue: Run a weekly report of all active biologic patients filtered by authorization end date. Route any patient whose approval expires within 45 days into the prior authorization specialist's immediate work queue.
• Standardize Clinical Chart Pre-Loads: Create structured templates inside the EHR requiring clinical documentation of prior step therapy failures (such as topical corticosteroids, methotrexate, phototherapy, or oral systemics) before submitting the initial PA request.
• Implement an Order-to-Schedule Lock: Program the practice scheduling system to block front-desk staff from booking phototherapy series or biologic administration slots until an authorization number is active, entered into the billing demographics, and mapped to the appropriate billing provider.
• Verify NDC-to-HCPCS Unit Mappings: Ensure your clinical billing team updates the 11-digit NDC and corresponding unit qualifier (UN, ML, GR, F2) to match exact payer compendia requirements for every buy-and-bill administration.

Managing Payer-Specific Nuances

Medicare MACs generally follow Local Coverage Determinations (LCDs) that do not require commercial-style prior authorization for standard phototherapy, but they enforce strict medical necessity documentation parameters and frequency limitations. In contrast, Medicare Advantage and Medicaid managed care organizations routinely require explicit authorization numbers submitted on the electronic claim.

When a CO-197 denial is issued improperly—such as when an authorization was on file, but the payer's automated claims adjudication engine failed to match the REF*G1 segment—do not immediately file a clinical appeal. Contact the payer's provider services department to request a telephone or portal-based claim reprocessing using the original authorization reference number. If the denial was caused by an erroneous rendering NPI or a transposed authorization digit, correct the claim data and submit a corrected claim within the payer's timely filing window.

If your practice is experiencing persistent prior authorization denials, write-offs, or revenue delays on biologics and specialty dermatology services, we can help identify the root causes. Contact DermBilling USA to request a comprehensive claims audit and evaluate your revenue cycle workflows.